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Abstract  
Purpose: Drug allergy documentation in the patient medical record varies in level of detail, and drug intolerances are often 
inappropriately documented as an allergy in the medical record. A pilot study was conducted to determine the impact of a pharmacy-
led drug allergy clarification service. 
Methods: The pilot quality improvement service was implemented in Fall 2016. General medicine patients were identified through daily 
census reporting and the electronic medical record (EMR) was reviewed within 72 hours of admission for documented drug allergies 
and/or intolerances. Patients were interviewed by a clinical pharmacist or a fourth year pharmacy student to determine a complete 
drug allergy and intolerance history.   
Results: A total of 55 patients were interviewed and received the pilot service. A drug allergy/intolerance was documented in EMR for 
54.5% (n=30) of patients interviewed. Of those 30 patients, 96.6% (n=29) were noted to have at least one discrepancy between EMR 
documentation and patient interview. The primary discrepancy noted was drug allergies or intolerances documented in the EMR 
without a description of the reaction.  
Conclusion: A pharmacy-led drug allergy clarification service was effective in identifying and clarifying EMR documentation of patients’ 
drug allergies and intolerances. Patients with incorrect or incomplete allergy documentation may receive alternative therapy, which 
could increase costs and lead to unwanted adverse effects or less effective treatment. As a result of the pilot study, the program has 
remained in effect and is being expanded to other units within the institution.  
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Purpose 
The true incidence of drug allergy/hypersensitivity reactions is 
unknown. In general, drug allergy documentation in the patient 
medical record varies in level of detail, from no description of 
the allergic event to single word descriptors (e.g. “rash”) to 
thorough explanation (e.g. “itchy rash over trunk”).1 
Additionally, drug intolerances or side effects are also often 
inappropriately documented as an allergy in the patient’s 
medical record.2-8 More accurate and comprehensive 
documentation of allergies improves patient care, as the 
provider can use the detail to determine if a medication can be 
safely administered to the patient. Patients with incorrect 
allergy documentation in the medical record may receive 
alternative therapy which could be less effective, lead to higher 
healthcare costs due to prolonged length of stay and/or drug 
costs, expose patients to unexpected adverse drug effects, and 
place limitations on future available therapeutic options if the 
disease or condition recurs.2 
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St. Vincent’s Birmingham (SVB) is a community hospital located 
in suburban Birmingham, Alabama.  In partnership with 
Samford University’s McWhorter School of Pharmacy, 
pharmacy faculty serve as affiliate clinical pharmacists and 
provide clinical services on the general medicine floor at SVB. In 
the course of the pharmacists’ usual practice, the pharmacy 
faculty will review patients’ medical records to conduct 
comprehensive medication and allergy assessments and 
provide recommendations to providers. Additionally, the 
faculty will conduct interviews of the patient and/or caregiver 
when needed to gather pertinent information related to 
medications, disease states, or allergies, which supports 
completion of  a more accurate and comprehensive assessment 
for pharmacy recommendations. Fourth-year pharmacy 
students who are completing an advanced practice pharmacy 
experience (APPE) rotation at the facility are also assigned to 
pharmacy faculty as a part of the faculty member’s University 
obligations. As a part of the general medicine APPE, these 
students assist the pharmacist with medication and allergy 
reviews using the patient’s medical record, and the students 
conduct patient/caregiver interviews for the above outlined 
purpose, when indicated. 
 
Throughout the pharmacists’ usual practice on the general 
medicine floor, errors and omissions in patients’ drug allergy 
and intolerance documentation within the medical record have 
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been noted.  Some examples of these errors/omissions include: 
allergies without any listed detail on the type or severity of 
reaction (allergy description: “n/a”, without detail); 
documentation with a one-word description of allergy with 
limited detail (e.g. penicillin – rash vs. penicillin – rash and 
hypotension); drug intolerances, sensitivities, or expected drug 
effects documented as a drug allergy (e.g. lorazepam – 
documented as severe allergy; reaction description: 
drowsiness); and documented drug allergy(ies) in the medical 
record that the patient does not endorse on interview. When 
discrepancies have been noted, the pharmacist or APPE student 
would communicate the information to the provider via face-
to-face or written medical record encounters. As a result of this 
anecdotal experience, this pilot project was developed with the 
intent to implement a quality improvement service to uniformly 
clarify patients’ allergy history information for a cohort of 
patients admitted on the general medicine floor. Any identified 
discrepancies between the medical record and patient 
interview were communicated to providers and the medical 
record was updated. The purpose of the pilot was to determine 
if the service should be continued on the floor and expanded to 
other areas of the institution.  
 
Methods 
Study design 
A pilot drug allergy clarification (DAC) quality improvement 
service was implemented during the fall of 2016. The service 
was conducted by clinical pharmacy faculty and fourth year 
APPE students. Prior to service implementation, drug allergy 
clarifications were not routinely conducted within the facility 
and a standardized format was not utilized for clarification 
interviews. A retrospective chart review was conducted of 
patients receiving the DAC service during the initial four weeks 
of the pilot.  Adult patients admitted to the general medicine 
floor were identified through daily census reporting within the 
electronic medical record (EMR) and were automatically 
eligible to receive the pilot service. Patients who were non-
verbal, non-English speaking, diagnosed with dementia, or 
classified as a poor historian in the medical record were 
excluded from receiving the intervention. This project received 
exempt status by the St. Vincent’s – Birmingham Institutional 
Review Board.  
 
DAC service 
The DAC service intervention was conducted by clinical 
pharmacy faculty and APPE students during the pilot [Figure 1]. 
Prior to participation in the DAC service, APPE students were 
required to complete a continuing education module on drug 
allergy clarification, available via Pharmacist’s Letter®, with a 
requirement of earning passing score of  >80%1. The students 
participated in role-play exercises with clinical faculty for skill-
building and observed clinical faculty while conducting the 
service on an eligible patient. Additionally, faculty observed 
students as they completed a minimum of two DAC 
interventions and provided formative feedback and 
opportunities for remediation of skills as needed. A 
standardized allergy clarification questionnaire was utilized 
throughout the DAC service to ensure consistency among 
clinician interviews [Appendix A]. 
 
Within 72 hours of admission, patients’ EMRs were reviewed 
for documented drug allergies and/or intolerances. Additionally 
during this timeframe, patients were interviewed by a clinical 
pharmacist or an APPE student to determine a complete drug 
allergy and intolerance history along with a description of the 
allergic reaction(s) or medication intolerance(s) – as 
appropriate. Following the interview, data from the EMR and 
patient interview were evaluated to determine if any of the 
following discrepancies were present: (type A) drug allergy or 
intolerance documented in the medical record without 
description of reaction; (type B) drug intolerance/sensitivity or 
known adverse effect of therapy documented in the medical 
record as an allergy; (type C) drug allergy documented in 
medical record that patient does not endorse on interview; or 
(type D) undocumented allergy or drug intolerance discovered 
upon patient interview. Discrepancies identified were 
communicated to the hospitalist via verbal communication, 
when feasible, and medical record documentation. 
Additionally, patients received education on characteristics of 
drug allergies and drug intolerances at the conclusion of the 
patient interview along with tailored education on their specific 
drug allergy or intolerance, as necessary. 
 
Outcome measures 
The primary outcome measures were the amount of patients 
with a confirmed true drug allergy upon interview and the total 
of the following discrepancies: drug allergy or intolerance 
documented in the medical record without description of 
reaction; drug intolerance/sensitivity or known adverse effect 
of therapy errantly documented in the medical record as an 
allergy; and undocumented allergy discovered upon patient 
interview. The rate of complete descriptions of the allergic 
reaction(s) or intolerance(s) among EMR documentation of 
patients with confirmed true drug allergy versus drug 
intolerance was evaluated as a secondary outcome.  
 
Drug allergy in this study was defined as symptoms of a type I 
immediate immunologic reaction, such as hives, itching, 
angioedema, acute asthma, and anaphylaxis. Drug intolerance 
was defined in this study as a sensitivity or adverse effect of 
therapy without an implicated immunologic reaction. 
 
Statistical methods 
Descriptive statistics were used to analyze the primary 
outcomes. Fisher’s exact test was utilized to evaluate the 
secondary outcome. An alpha value of p < 0.05 was considered 
significant.  Statistical analyses were conducted using SPSS (IBM 
Corp. Released 2015. IBM SPSS Statistics for Windows, Version 
23.0. Armonk, NY: IBM Corp). 
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Results 
During the initial four weeks of the pilot, a total of 55 patients 
were interviewed and received the pilot DAC service. The mean 
patient age was 57.1 years, and the majority of patients were 
female (57.2%). A drug allergy or intolerance was documented 
in the medical record for 54.5% (n=30) of patients interviewed, 
with a total of 44 discrete drug allergies documented within the 
EMRs of all patients interviewed. Of the documented drug 
allergies, true drug allergy was confirmed in the majority of 
cases (81.8%, n=36). 
 
Of the 30 patients with a documented allergy or intolerance, 
96.6% (n=29) patients were noted to have at least one 
discrepancy between EMR documentation and patient 
interview. A total of 45 discrete discrepancies between EMR 
documentation and patient interview reports were noted. 
Descriptions of identified discrepancies are provided in Figure 
2. It is important to note that of the three type D discrepancies 
observed, one of which was classified as a true drug allergy 
discovered upon interview in a patient with “no known drug 
allergies” documented within the EMR.  
 
The most common discrepancy identified was a drug allergy or 
intolerance documented in the EMR without a description of 
the reaction (75.6%). Upon interview, the most commonly 
reported reactions to drug therapy were hives/rash (n=15), 
anaphylaxis/angioedema (n=6), and hallucinations (n=4). A 
comparison of EMR documentation in confirmed cases of true 
drug allergy (n=36) versus confirmed drug intolerance (n=8) 
indicated there was no significant difference in the 
completeness of EMR descriptions of the reaction(s) or 
intolerance(s) among groups (p=0.5475, Table 1). 
 
Medications implicated in drug allergy and intolerance 
discrepancies in this study are described in Table 2. Of the 
noted discrepancies, antibiotics were the medication class most 
commonly identified in type A and D discrepancies. Whereas, 
opioids were more commonly noted in type B discrepancies.  
 
Conclusion 
A pharmacy-led DAC service was effective in identifying and 
clarifying EMR documentation of drug allergies and 
intolerances experienced by the majority of patients 
interviewed during the pilot service. The DAC service was not 
time-intensive and was seamlessly incorporated into routine 
clinical care on the floor. Median (IQR) time spent completing 
the service in those without an identified discrepancy was three 
minutes (3), whereas the median (IQR) time spent clarifying 
allergy or intolerance in those with identified discrepancies was 
10 minutes (4.5). 
 
The primary discrepancy noted with implementation of the 
pilot DAC service was drug allergies or intolerances 
documented in the medical record without a description of the 
reaction. This could lead to inappropriate prescribing and 
unnecessary avoidance of beneficial therapies. Additionally, 
more toxic and costly therapies may be prescribed in cases of 
type A and type B discrepancies due to incomplete or errant 
EMR documentation that suggests drug allergy in cases of 
intolerance. Our study is not the first evaluation to identify the 
prevalence of incomplete EMR documentation related to 
reported drug allergies and intolerances. An evaluation 
conducted by Burrell et al. revealed that EMR records in 
approximately 47% of the institutions’ patients with a 
documented drug allergy/intolerance were incomplete and 
lacked corresponding information describing the drug reaction. 
Following implementation of a pharmacist-driven protocol to 
improve documentation of the nature of drug intolerances and 
reactions, the frequency of complete documentation increased 
from a rate of 52-62% to 60-76%.9 Another study, aimed at 
increasing awareness of the importance of complete chart 
documentation in postoperative elective surgical patients, 
evaluated 40 patient charts and found that allergy status 
documentation was absent in 17.5% of charts, including 5% of 
those with a known drug allergy. After bringing awareness 
through education, a subsequent chart review showed allergy 
status documentation improved to 87% and failure to 
document a known allergy decreased to 2%. The authors 
concluded that “collaboration with the pharmacists could also 
allow a 'best possible medication history to be taken on the day 
of admission and thus reduce risk to patient safety.”10 
Other studies have been published examining the impact of 
pharmacist-led interventions to clarify medication allergies, 
with the majority focused on clarification of antimicrobial drug 
allergies. Sigona et al. conducted drug allergy clarification 
interviews on 32 adults with documented beta-lactam allergy 
who were receiving non-penicillin antibiotics and noted a 
discrepancy between the EMR-reported allergy and interview 
report in 34.4% of patients.11 Similarly, Bouwmeester et al. 
reported an evaluation of pharmacist interventions to clarify 
drug allergy reports in a pediatric hospitalized patient 
population and found that 14% of documented cases were a 
true allergy vs. 31% of cases determined to be incorrectly 
reported drug allergies.3 Our study presents an evaluation of 
the impact of a comprehensive DAC service to alert providers 
to discrepancies among EMR documentation and patient 
interviews for reactions associated with any prescription or 
non-prescription product. 
 
This study has several limitations. Given the pilot nature of the 
program, a small, convenience sampling of patients was utilized 
in a single center, which may limit external validity. Type 1 
immunologic reactions were determined to be true drug allergy 
in this study and delayed type reactions were not considered 
within the definition. However, it should be noted that there 
were no reports suggestive of type II and III reactions among 
patients interviewed in this study.  Lastly, this study is an 
evaluation of a DAC service in an inpatient, general medicine 
setting. Assessment of the service among various levels of care 
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may provide beneficial insight into the effectiveness of the DAC 
intervention. 
 
More comprehensive documentation of drug allergies and 
intolerance is warranted within the medical record and should 
be confirmed at the time of hospital admission. Patients with 
incorrect or incomplete allergy documentation may receive 
alternative therapy, which may be more costly, less effective, 
and associated with unexpected adverse drug effects.  As a 
result of the pilot findings, the program has remained in effect 
and is being expanded to other units within the facility.  
Healthcare systems should consider implementation of a 
similar service for systematic clarification of drug allergies and 
intolerances to ensure providers are equipped with accurate 
information to guide therapeutic decision-making.  
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Table 1. 
 
Completeness of EMR descriptions of allergic reaction(s) and drug intolerance 
 Patients with confirmed 
drug allergy 
n (%) 
Patients with confirmed 
drug intolerance 
 
p-value 
Total 
 
36 8  
Medical record 
documentation 
   
Complete with 
description of 
reaction/intolerance 
 
7 (19.4) 1 (12.5) 0.5475 
Incomplete 
description of 
reaction/intolerance 
29 (80.6) 7 (87.5)  
 
 
 
 
 
 
 
Table 2. 
 
Discrepancies in drug allergies and intolerance by medication class 
Medication Class Type Aa Type Bb Type Cc Type Dd Number of drug 
allergies/intolerances 
identified by class 
Antibiotics 14 0 1 1 16 
Opioids 5 3 0 1 9 
NSAIDs 2 2 0 0 4 
Other 13 3 0 0 16 
atype A: drug allergy or intolerance documented in medical record without description of reaction 
btype B: drug intolerance/sensitivity or known adverse effect of therapy documented in the medical record as an allergy 
ctype C: drug allergy documented in medical record that patient does not endorse on interview 
dtype D: undocumented allergy or drug intolerance discovered upon patient interview 
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Figure 1. DAC Service Flowchart 
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Appendix A. 
 
DAC Standardized Questionnaire 
 
1. Have you ever taken a medicine that caused a 
reaction or side effect? If yes, continue to #2; if 
no, skip to #14. 
2. What was the medication(s)? 
3. Can you tell me why the medication(s) [which 
caused the reaction/side effect] was prescribed 
for you? 
4. Do you remember the year [or how old you 
were] when the reaction/side effect to the 
medication(s) occurred? If yes, ask the specific 
year or patient’s age. 
5. Please describe the reaction or side effect. Tell 
me how the reaction/side effect made you feel.  
6. Did you use any prescription medication, over-
the-counter medication, or non-medication 
treatment to stop the reaction/side effect or to 
make you feel better after the reaction/side 
effect? If yes, ask the specific medication or 
non-drug therapy used. 
7. After you stopped taking the medication(s) 
[that may have caused the reaction/side 
effect], what happened? Did the reaction/side 
effect resolve? 
8. At the time of the reaction/side effect, were 
you taking any other medication(s) [including 
over-the-counter and herbal products]? 
9. Since taking the [offending] medication(s), have 
you ever had the same reaction occur but with 
a different medication(s)? 
 
 
10. Did you ever take the same medication(s) [that 
you believe caused the reaction/side effect] 
again after experiencing the reaction/side 
effect? If yes, continue to #11; if no, skip to #12. 
11. What happened when you took the same 
medication(s) again? 
12. Have you ever taken a medication(s) similar to 
the offending medication after this reaction? 
Note: interviewer to provide prompts to aid in 
patient understanding; e.g., in allergy to 
penicillin VK, the interviewer may ask about 
use of amoxicillin.  If yes, continue to #13, if no, 
skip to #14. 
13. Did you have a reaction or side effect to this 
similar medication? If yes, please describe the 
reaction. 
14. Have you ever experienced any of the following 
symptoms while taking a prescription or over-
the-counter medication:  
a. itching, redness, or swelling of the 
skin; 
b. itching, redness or swelling of the 
eyes; 
c. trouble breathing or shortness of 
breath; 
d. swelling of the lips and eye lids; 
e. stomach pain 
If yes, which symptom(s) occurred and what 
medication(s) were you taking? 
 
 
 
 
 
 
